Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Goldman Sachs on Eli Lilly (LLY): 'see the stock weakness as an overreaction'
May 4, 2026 9:27 AM EDTGoldman Sachs analyst Asad Haider reiterated a Buy rating and $1,283.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "Shares of LLY are down ~2% in early trading following a post in the FDA Adverse event monitoring system of a patient... More
Eli Lilly & Co. (LLY) Tops Q1 EPS by $1.58, Beats on Revenue; Offers Strong Guidance
April 30, 2026 6:48 AM EDTEli Lilly & Co. (NYSE: LLY) reported Q1 EPS of $8.55, $1.58 better than the analyst estimate of $6.97. Revenue for the quarter came in at $19.8 billion versus the consensus estimate of $17.6 billion.
GUIDANCE:
Eli Lilly & Co. sees FY2026 EPS of $35.50-$37.00, versus... More
